Mumbai:Marksans Pharma Limited has announced that its wholly owned subsidiary in UK, Relonchem Limited, has received marketing authorizationfrom the UK Medicines and Healthcare products Regulatory Agency (MHRA)for its two products. The latest approvals are part of a broader string of UK MHRA authorizations received by Relonchem throughout the year. In August, Relonchem received marketing authorisation for three strengths of its Metformin Hydrochloride Relonchem Prolonged Release Tablets. In June 2025, the subsidiary secured marketing authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution. In late May, Relonchem received marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution, followed by approval for Sennosides 7.5 mg Tablets earlier in the month. In March, the UK MHRA approved Baclofen 10 mg Tablets, a medication used to relax specific muscles in the body, relieving spasms, cramps, and tightness associated with multiple sclerosis or spinal injuries. The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK. Back in February, Relonchem also received authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets).
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!